Please assess the completion status of the following clinical trial:

Trial Title: AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 \<85 years~* Patient is currently treated with an ACEI~* Patient must have acute angioedema attack caused by an ACEI~* Treatment should be administrated within 10 hrs after onset by an ACEI~* Patient with angioedema of head and /or neck (face, lips, cheeks, tongue, soft palate/uvula, pharynx and larynx)~* At least one moderate to severe severe angioedema symptom as assessed by the investigator, requiring a medical intervention~* Signed written Informed Consent Form~Exclusion Criteria:~* Diagnosis of angioedema that was not caused by ACEI: e.g. hereditary angioedema (C1-INH deficiency), allergy, anaphylaxis, insect bite, trauma, infection, abscess, tumor, post-radiation or post-operative or processes related to salivary glands and others where it is unlikely that the ACEI is causing the angioedema~* Participation in a clinical trial of another investigational medicinal product (IMP) within 30 days~* Patients with acute urticaria~* Patients with a medical history of any angioedema before taking an ACEI~* Patients with an acute rash or hives in the face or somewhere else~* Unstable angina or acute myocardial infarction~* Acute heart failure~* Serious concomitant illnesses that the physician considers to be a contraindication for participation in the trial~* Pregnancy and/or breast-feeding~* Mental condition rendering the patients, in the opinion of the investigator, unable to understand the nature, scope and possible consequences of the study;~* Unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for the follow-up visit, or unlikely to complete the study for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).